Hepatitis B and C

An estimated 325 million people worldwide are living with viral hepatitis B and C, with roughly 80% of people living with hepatitis B and C lacking prevention knowledge, testing and treatment services. In this application note, Biorbyt provides details of their available HBV antigens and HBC recombinant antigens that are all suitable for use in ELISA, to help aid the research into finding a cure.